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The microbiota that resides in the gastrointestinal tract provides essential health 
 benefits to the host. In particular, they regulate immune homeostasis. Recently, several 
evidences indicate that alteration in the gut microbial community can cause infectious 
and  non-infectious diseases. Tuberculosis (TB) is the most devastating disease, inflicting 
mortality and morbidity. It remains unexplored, whether changes in the gut microbiota 
can provoke or prevent TB. In the current study, we have demonstrated the antibiotics  
driven changes in the gut microbial composition and their impact on the survival of 
Mycobacterium tuberculosis (Mtb) in the lungs, liver, and spleen of infected mice, 
compared to those with intact microbiota. Interestingly, dysbiosis of microbes showed 
significant increase in the bacterial burden in lungs and dissemination of Mtb to spleen 
and liver. Furthermore, elevation in the number of Tregs and decline in the pool of  IFN-γ- 
and TNF-α-releasing CD4 T cells was noticed. Interestingly, fecal transplantation in the 
gut microbiota disrupted animals exhibited improved Th1 immunity and lesser Tregs 
population. Importantly, these animals displayed reduced severity to Mtb infection. This 
study for the first time demonstrated the novel role of gut microbes in the susceptibility 
to TB and its prevention by microbial implants. In future, microbial therapies may help in 
treating patients suffering from TB.
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inTrODUcTiOn
Approximately one-third of the world population is infected with Mycobacterium tuberculosis (Mtb), 
but only 5–10% contract active tuberculosis (TB), whereas the remaining 90–95% develop effec-
tive immunity (1). An intriguing possibility is that there exists an intricate balance between host 
and pathogen; where the host develops remarkably powerful immunity, which does not allow the 
pathogen to replicate and inflict disease. However, any disturbance in this finely tuned balance may 
lead to the development of TB.
The gut microflora is an immense health asset for human beings (2). The mammalian gut har-
bors trillions of commensals. These microbes influence not only local but also systemic immunity. 
Recently, various reports signify that the gut microbes can modulate, tune, and tame the host 
immune response (3). Importantly, an ever-growing number of disorders have been linked with 
resident microbiota and gastrointestinal diseases, such as intestinal bowel disease (IBD) (4). More 
importantly, imbalance in the gut microbiome has been shown to be associated with extra-intestinal 
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ailments such as cancer, cardiovascular diseases, obesity, and 
non-alcoholic fatty liver disease (5–8). Consequently, it advocates 
the significance of the microbial composition that can influence 
our health. The microbiota provides a fine equilibrium to the host 
by regulating immune homeostasis (9).
Antibiotics are often used in the clinics to treat bacterial 
infections, but they are also major factor in disturbing the 
gut microbial composition (10). Antibiotics driven changes 
in gut microbiota provoke host susceptibility to enteric infec-
tion. However, impact of antibiotics induced changes in gut 
microbiota on the TB progression has not yet been studied. 
Therefore, we designed our study taking into consideration two 
models pre- and post-antibiotics treatment models of experi-
mental TB. In pre-antibiotics model, animals were treated with 
broad spectrum antibiotics prior to Mtb infection, mimicking 
a condition wherein the individuals undergo treatment with 
various antibiotics before being exposed to Mtb and may have 
some impact on the progression of TB. In post-antibiotics 
model, animals were treated with antibiotics after Mtb infec-
tion. Post-antibiotics treatment study was designed to consider 
those individuals who are exposed to Mtb and take broad 
spectrum antibiotics for some other infections. Interestingly, 
we observed that animals with disruption in gut microbiota 
after both pre- and post-antibiotics treatment showed higher 
susceptibility toward Mtb and promoted its dissemination. 
Intriguingly, fecal transplant (FT) from normal mice recon-
stituted the gut microbiota of antibiotics treated animals, 
which subsequently decreased the Mtb load in the lungs and 
prevented the dissemination of the disease. In essence, this 
finding signifies that the alteration in the gut microbiota may 
facilitate the development of TB.
MaTerials anD MeThODs
animals
C57BL/6 mice, 6–8 weeks were procured from the CSIR-Institute 
of Microbial Technology (IMTECH), Chandigarh, India.
ethics statement
All the experiments were approved by the Institutional Animal 
Ethics Committee of the IMTECH and performed according to 
the National Regulatory Guideline issued by Committee for the 
Purpose of Supervision of Experiments on Animals (No. 55/1999/
CPCSEA), Ministry of Environment and Forest, Government of 
India.
cultivable Microbes
Fecal samples (200–300 mg) were collected aseptically in 1 ml of 
1× PBS. Samples were homogenized and supernatant were col-
lected after centrifuging samples at 2000 rpm for 2 min to pellet 
down debris. Later, serial dilutions were made and supernatants 
(100 μl) were plated on different media to culture both aerobic 
and anaerobic microbes. To cultivate anaerobic microbes, plates 
were kept in vacuum tight container in the presence of anaerobic 
gas pack (Himedia, Mumbai, India) for overnight.
Bacterial Diversity
To assess the bacterial diversity, supernatant from fecal samples 
was plated on different media to culture both aerobic and anaero-
bic microbes for overnight, as described above. The identification 
of colony morphotypes was carried out using four parameters: 
colony size, form, color, and texture. A phenotypic variant was 
considered when it differed in at least one of the referred mor-
phological parameters. Diversity was calculated by counting the 
total number of different colonies of bacteria grown on different 
media plates. Total different colonies from the feces of healthy 
animals were considered as a reference number. Decrease in the 
bacterial diversity was calculated as (reference number −  total 
different colonies calculated from infected or pre-antibiotics or 
post-antibiotics) × 100/reference number.
Pre-antibiotics-Treated Mtb Model  
(Pre-antibiotics)
Mice were pre-treated with vancomycin (100 mg/l), polymixin B 
(60 mg/l), carbenicillin (50 mg/l), trimethoprim (20 mg/l), and 
amphotericin B (50 mg/l) ad libitum in drinking water for 21 days. 
The water containing antibiotics were replaced on every 3 days. 
Control mice were fed antibiotics free water. After 21 days, mice 
were challenged with Mtb (H37Rv) with deposition of 100 CFU 
in the lungs. The animals were administered antibiotics in the 
water for additional 21 days. Later, the mice were sacrificed, and 
tissues were harvested aseptically for immunological, microbio-
logical, and histopathological studies. Pictorial representation of 
methodology is embedded in Supplementary Material.
Post-antibiotics-Treated Mtb Model  
(Post-antibiotics)
Mice were challenged with Mtb with the deposition of 100 CFU 
in the lungs. After 21  days, mice were treated with antibiotics 
for subsequent 21 days with replacement of water every 3 days. 
Later, mice were sacrificed, and tissues were harvested asepti-
cally for immunological, microbiological, and histopathological 
studies. Pictorial representation of methodology is embedded in 
Supplementary Material.
reconstitution of gut Microbiota
Antibiotics-treated mice underwent FT to reconstitute the gut 
composition. Fecal samples (200–300 mg) from five healthy mice 
were collected aseptically in five separate tubes in 1 ml of 1× PBS. 
Samples were homogenized and supernatant was collected after 
centrifuging samples at 2000 rpm for 2 min to pellet down debris. 
Supernatant slurry was collected and pooled together, and 100 μl 
was gavaged into mice within 15–20 min of excretion. Five doses 
with a gap of 3 days interval were orally administered to mice 
prior to 15 days of sacrificing animals. Pictorial representation 
of methodology is embedded in Supplementary Material as 
Methodology 2.
expression of iFn-γ, TnF-α, and  
Foxp3 by Flowcytometry
Spleen was harvested, and single-cell suspension was prepared. 
Briefly, lymphocytes from spleen were prepared by lysing RBCs 
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with ACK lysis buffer (NH4Cl 0.15M, KHCO3 10  mM, EDTA 
88 mM), washed 3× with PBS, and resuspended in RPMI-1640-
FBS-10%. Viability of the cells was assessed by trypan blue 
dye-exclusion method. The experiments were performed to 
detect intracellular cytokines and Foxp3 expression on T cells. 
To detect cytokines, splenocytes were restimulated in  vitro 
with purified protein derivative (PPD). Splenocytes stimulated 
with PPD (20 μg/ml) were cultured for 48  h at 37°/CO2 (5%). 
During last 4 h, cells were incubated with phorbol 12-myristate 
13-acetate (PMA; 20 ng/ml) and ionomycin (1 μM) plus brefel-
din A (5 μg/ml) for 2 h. The cells were stained with anti-CD4 
Abs. After surface staining, cells were washed and resuspended 
in permeabilization-fixation solution (BD Cytofix/Cytoperm 
kit; BD Pharmingen, San Diego, CA, USA), and intracellular 
cytokine staining was performed with fluorescence-labeled Abs 
to TNF-α, IFN-γ, according to manufacturer’s protocol. FoxP3 
staining was performed (Foxp3/Transcription Factor Staining 
Buffer Set, Ebioscience) according to manufacturer’s instruc-
tions. Data were collected using FACS Aria and analyzed using 
the BD DIVA software.
statistical analysis
Statistical analysis was done using unpaired Student’s t-test and 
one-way ANOVA for group analysis using the Graph pad prism 
software 6.
resUlTs
antibiotics Treatment Modulates the gut 
Microbiota composition
Recent studies have shed new light on an impact of antibiotics 
on the gut microbes, which eventually may affect the severity 
of disease. Hence, we were curious to explore the influence of 
altered gut microbiota on the progression of TB. To test this 
hypothesis, mice were fed with broad spectrum antibiotics, prior 
to Mtb infection (pre-antibiotics) (for detailed methodology, 
please see Supplementary Material). Broad spectrum antibiotics 
were selected for the study. These antibiotics exhibited no impact 
on Mtb recovery in a Middlebrook 7H11 agar formulation 
(11). Animals treated with antibiotics for initial 5 days showed 
significant (p < 0.001) decrease in the CFU of the gut microbiota 
(Figure 1A). In contrast, when the antibiotics treatment was pro-
longed for 42 days, significant (p < 0.001) elevation in the number 
of microbes was observed (Figure 1A). Similar results (p < 0.01) 
were observed in the case of mice prior challenged with Mtb 
and then treated with antibiotics (post-antibiotics) (Figure 1B). 
Results suggest that initially antibiotics sensitive bacteria were 
eliminated, which resulted in the decline of CFUs (Figure 1A). 
However, later antibiotics resistant microbes predominated by 
over proliferation. However, we observed significant (p < 0.01) 
decrease in the diversity of the microbial taxa (Figure 1C), since 
the majority of the colonies were of sister clones, as identified 
through their morphology. Furthermore, we noticed enlargement 
in the size of cecum (Figure 1D). This change in the intestine was 
due to the decreased ability of antibiotics-treated mice to digest 
the food, as it was apparent by the presence of indigested food in 
the intestine. Similar results were observed in post-antibiotics-
treated Mtb animals (Figure 1D).
animal Treated with antibiotics showed 
higher Mtb Burden in the lungs and its 
Dissemination
The aim of the study was to assess the consequence of antibiotics 
driven alteration in the gut microbiota on Mtb survival in Mtb 
challenged mice. Interestingly, we observed that disruption of 
microbiota in pre-antibiotics (p  <  0.05) and post-antibiotics 
(p < 0.01) treatment, significantly enhanced the growth of Mtb 
in the lungs of the infected animals (Figures 2A,B). This informa-
tion was further corroborated with histopathological analysis of 
the lungs (Figure 2C). Mtb-infected mice on pre-antibiotics treat-
ment showed larger and greater number of granulomas in their 
lungs, compared to control (Mtb infected, but not treated with 
antibiotics) (Figure 2C, upper panel). In addition, we observed 
significant increase in the granulomatous or tuberculous region 
(p  <  0.01) in lungs of pre-antibiotics Mtb-infected animals 
(Figure 2D). Similar trend was observed in the post-antibiotics-
treated animals as shown in histopathological images (Figure 2C, 
lower panel).
Dissemination of Mtb from lungs to other parts of the body 
is a probable factor responsible for extra-pulmonary infection. 
Interestingly, significant increase in the bacterial load of Mtb 
was observed in the spleen (p <  0.01) and liver (p <  0.05) of 
pre-antibiotics Mtb-infected model (Figure  3A). Similarly, 
post-antibiotics infected mice showed greater Mtb burden in the 
spleen (p < 0.01) and liver (p < 0.01), as compared to controls 
(Figure 3B). These data suggest that gut the microbiota play a 
crucial role in restricting the proliferation and dissemination of 
Mtb.
Fecal Transplantation in antibiotics-
Treated Mice reconstitutes the gut 
Microbiota
Before sacrificing animals, both pre-antibiotics and post-antibi-
otics-treated groups were fecal transplanted orally. Interestingly, 
we observed significant (p < 0.001) decline in the number of gut 
microbes in pre-antibiotics model after fecal transplantation and 
their number was comparable with normal mice (Figure  4A). 
Furthermore, there was significant (p < 0.001) but partial restora-
tion in the microbial diversity, as noticed through morphology 
of microbes in FT group (Figure S1 in Supplementary Material). 
The variation was not resilient, i.e., did not return to its original 
percentage. It suggests that lowering of microbial diversity by 
antibiotics treatment could not be fully restored to its original 
frequency after FT for 15 days. It is reported that antibiotics treat-
ment decreases the number of beneficial microbes (12). Therefore, 
we have confirmed the alteration in gut microbiota due to anti-
biotics treatment, by identifying microbes in the fecal samples 
by RT-qPCR. We observed significant increase in the number of 
Enterococcus (p < 0.05) but decline in the level of Bifidobacterium 
(p < 0.01), Lactobacillus (p < 0.05), Campylobacter (p < 0.05), and 
Bacteroides (p < 0.05) (Figure 4B). These results further support 
the partial reconstitution of gut microbial composition through 
FigUre 1 | antibiotics altered the gut microbial composition. (a–c) Mice were pre-treated with broad spectrum of antibiotics for 42 days. In between, on day 
21, animals were challenged with Mtb. (a) Cultivable microbes on 5 and 42 days; (c) microbial diversity on 42 days were enumerated in fecal samples of treated 
mice. (B) In post-antibiotics model after 21 days of Mtb challenge, mice were treated with antibiotics daily for subsequent 21 days. Later, cultivable microbes were 
enumerated in the fecal samples. (D) Increment in the size of cecum in both pre-antibiotics and post-antibiotics animals was measured; bar graph represents the 
length (centimeters) of cecum. Data shown as mean ± SEM are representative of three independent experiments (n = 4–5 animals/group) (*p < 0.05, **p < 0.01, 
and ***p < 0.001).
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FT. This information was further corroborated by PCR (Figure 
S2 in Supplementary Material). As compared to control animals 
(2.3  cm), antibiotics-treated group showed increase in the size 
of cecum (3.2 cm). Interestingly, FT restored the size of cecum 
to near normal (2.6) (Figure 4C). Furthermore, as compared to 
controls, the histopathological studies conducted on the ileum 
FigUre 2 | Disturbance in gut microbiota by antibiotics increased the survival of Mtb in the lungs and its dissemination to other organs. Mice treated 
with antibiotics prior and post exposure to Mtb infection. Later, animals were sacrificed, and lungs were isolated. Bacterial burden in (a) pre-antibiotics and (B) 
post-antibiotics-treated group was estimated by plating serial dilutions of lung homogenate on 7H11 agar plates. Colonies were enumerated on 21 days of plating. 
Bar graph depicts the bacterial burden in lungs. Data shown as mean ± SEM are representative of three independent experiments (n = 4–5 mice/group). (c) 
Histopathology sections of lungs of pre-antibiotics and post-antibiotics group were H&E stained and imaged at a magnification 40×. (D) Bar graphs depict the 
percentage of tuberculous region of pre-antibiotics Mtb group. Data are representative of three independent experiments (n = 4–5 animals/group) (*p < 0.05 and 
**p < 0.01).
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of pre-antibiotics-treated animals exhibited distorted structure 
of microvilli. The microvilli structure of ileum was reinstated 
to normal in the FT animals (Figure 4D). Similar results were 
observed in post-antibiotics model (Figure S3 in Supplementary 
Material). It was interesting observation that FT recovers antibi-
otics associated abnormities.
Fecal Transplantation restricts the 
growth as well as Dissemination of Mtb
Since, we observed significant augmentation in the growth of 
Mtb in the lungs of pre-antibiotics (p < 0.05) and post-antibiotics 
(p < 0.01) groups (Figures 2 and 3), therefore we thought to study 
the influence of FT on pre-antibiotics and post-antibiotics animals 
infected with Mtb. Interestingly, FT significantly reduced the bac-
terial load in the lungs (p < 0.001) and spleen (p < 0.01) of both 
pre- and post-antibiotics mice exposed to Mtb (Figures 5A,B).
We also examined the progression of disease by studying the 
histopathological changes in the lungs. As compared to control 
group, larger size and number of granulomas in the lungs of 
pre- as well as post-antibiotics group were noted (Figures 5C,D). 
It was observed that antibiotics-treated mice after FT, exhibited 
granulomas with smaller size and number, lesser infiltration of 
lymphocytes, and consolidated lung architecture, compared to 
antibiotics group (Figures 5C,D). These results suggest that gut 
microbiome can contribute in controlling Mtb growth and its 
dissemination.
antibiotics Treatment augments  
Tregs but suppresses Th1 cells
The role of Th1 cells is established in protection, whereas Tregs 
promote susceptibility to TB. Consequently, it was imperative 
to analyze the impact of antibiotics treatment on Tregs and Th1 
FigUre 3 | Disrupted gut microbiota promotes the dissemination of 
Mtb. Mice were treated with (a) pre-antibiotics and (B) post-antibiotics to 
Mtb infection. After 42 days, mice were sacrificed, and Mtb load was 
estimated in the spleen and liver by enumerating CFUs. Bar graph depicts 
the Mtb load. Data shown as mean ± SEM are representative of three 
independent experiments (n = 4–5 animals/group) (*p < 0.05 and 
**p < 0.01).
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cells and correlation in the modulation in their frequency with 
predisposition to TB. We observed substantial decline in the 
expression of IFN-γ and TNF-α upon treatment with antibiot-
ics (Figures  6A,C). It was of interest to note the restoration 
of the production of IFN-γ and TNF-α in the mice with FT 
(Figures 2 and 3). Expression of IFN-γ in the spleen was further 
confirmed by RT-qPCR (Figure  6B). In contrast, antibiotics 
treatment augmented the frequency of Tregs, whereas FT 
downregulated their number as evidenced by the expression of 
Foxp3 (Figure 6D). This observation suggests that the antibiot-
ics driven fluctuation in the gut microbiota can modulate the 
frequency of Tregs and Th1 cells, which may be responsible for 
proneness to TB.
DiscUssiOn
Tuberculosis is one of the world’s leading killer diseases with 
approximately two million deaths and eight million new cases 
annually. It is public health and economic burden on the 
country (13). However, majority of Mtb exposed individuals 
remain asymptomatic but exhibit varying level of immunity 
against Mtb infection. Several host factors have been identi-
fied in both mice and humans that contribute to susceptibility 
toward Mtb infection. The nramp1/SLC11A1 confers resistance 
in the murine model of TB, typhoid, and leishmaniasis (14). The 
role of diet also considerably contributes in prompting disease 
symptoms (15).
Recently, research related to gut microbiota has gain consid-
erable impetus, following the observation of its correlation with 
many immune disorders (16, 17). Shifts in the composition of 
the microbiota, whether induced by dietary changes, antibiotics 
treatment, or invasive pathogens, can disturb the balance of gut 
microbes and dysregulate the function of local as well as systemic 
immune system (9, 18, 19). Perturbation in the gastrointestinal 
microbiota composition is also strongly associated with allergies 
and asthma (12, 20).
Current study revealed the role of gut microbiota in control-
ling the pathogenesis of TB. Key findings emerged from the 
study suggest that disruption of gut microbiota with antibiotics 
of Mtb-infected animals revealed: (i) significant alteration in 
the gut microbiota; (ii) higher Mtb burden in the lungs; (iii) 
dissemination of Mtb to spleen and liver; and (iv) fecal implants 
reconstituted the gut microbiota and recuperated TB by declining 
the Mtb burden.
We selected antibiotics that were effective against both Gram-
positive and -negative bacteria. Furthermore, dose of antibiotics 
was carefully chosen that showed no effect on Mtb viability, 
even when administrated for 42 days. Importantly, the selected 
dose significantly induced dysbiosis in the gut. Importantly, 
alteration in gut microbiota promotes the survival of Mtb in 
the lungs. This finding emphasizes that composition and func-
tion of the gut community are important factors in conferring 
host resistance to invading pathogens. Our study revealed very 
interesting findings that antibiotics mediated disruption of gut 
microbiota not only increases the growth of Mtb in the lungs 
but also promotes its dissemination to other organs. Impact of 
antibiotics driven changes in gut microbiota on Mtb survival 
was further supported by fecal transplantation. Interestingly, 
fecal transplantation of antibiotics-treated mice restores the gut 
microbiota and decreases the Mtb burden in their lungs and 
prevents dissemination to spleen.
Microbiota plays an active role in the development and func-
tion of both pro- and anti-inflammatory T-cell pathways (21, 22). 
Frequency of the gut microbiota should be well tuned to mount 
host response against pathogens. Imbalance in the number of 
FigUre 4 | Fecal transplantation reconstitutes the gut microbiota. (a) Pre-antibiotics mice were administered five doses of FT, 15 days prior to sacrificing 
animals. Later, (a) enumeration of cultivable microbes was assessed in the fecal samples. (B) Alteration in the number of microbes, such as Enterococcus, 
Bifidobacterium, Lactobacillus, Campylobacter, and Bacteroides, was studied in the fecal samples by RT-qPCR. (c) Increment in the size of cecum was measured. 
(D) Histopathology sections of ileum were H&E stained and photomicrographs are shown at 100× magnification. Data shown as mean ± SEM are representative of 
two independent experiments (n = 4–5 animals/group) (*p < 0.05, **p < 0.01, and ***p < 0.001).
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Tregs changes the microbial composition and vice  versa (23). 
CD4 T cells are the major players in imparting immunity 
against Mtb. It is important to mention that the gut microbiota 
contributes substantially in the development of CD4 T cells, 
both within and outside the intestine (12, 24). We also observed 
that mice treated with antibiotics showed suppression of Th1 
immunity but increase in the frequency of Tregs. Fascinatingly, 
fecal transplantation of antibiotics-treated mice restored the 
gut microbiota and reinvigorated immunity by augmenting 
the pool of IFN-γ and TNF-α releasing Th1 cells. In contrast, 
inhibition in the population of Tregs was noted. Currently, it is 
difficult to explain how this phenomenon is operating. However, 
this observation is quite interesting and may open a new line of 
investigation.
FigUre 5 | restoration of gut microbiota restrains the growth of Mtb in the lungs and prevents its dissemination. Mice with (a,c) pre-antibiotics and 
(B,D) post-antibiotics treatment were provided five doses of FT, 15 days prior to sacrificing. Later, Mtb load was estimated in lungs and spleen. Bar graph depicts 
the Mtb load. Histopathology sections of lungs of (c) pre-antibiotics and (D) post-antibiotics-treated group were H&E stained and imaged at 40× magnification. 
Data shown as mean ± SEM are representative of two independent experiment (n = 5 animals/group) (*p < 0.05, **p < 0.01, and ***p < 0.001).
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FigUre 6 | Dysbiosis of gut microbiota imbalanced the frequency of Th1 and Tregs cells. Mice with pre-antibiotics treatment were provided five doses of 
FT, 15 days prior to sacrificing. Later, intracellular expression of (a) IFN-γ, (c) TNF-α, and (D) FoxP3 was monitored in CD4-gated T cells by flowcytometry. (B) IFN-γ 
expression was detected at mRNA level by RT-qPCR. Data shown are representative of two independent experiments (n = 4–5 mice/group).
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Antibiotics have been a cornerstone of innovation in the field 
of public health, but their negative effect on immune system 
and health cannot be ignored. Antibiotics driven compositional 
changes in the intestinal microbiota lead to severe dysregulation 
in the physiological and immunological intestinal homeostasis, 
creating serious and adverse consequences for the host (25, 26). 
To overcome such effect, new treatment strategies should be 
developed and designed to counteract the negative effect of anti-
biotics. One strategy could be to provide probiotics to supplement 
antibiotics induced deficits in the microbiota. Another, yet better 
approach could be to use immunomodulators to enhance the effi-
cacy of immune system to combat infectious agents. With better 
understanding of the correlation between gut microorganisms 
and Mtb, one hope is that their manipulation/supplementation 
might prove to be a future targeted therapy for treating diseases. 
Advances in understanding how gut microbiota regulates the 
pathogenesis of TB, may pave a novel way toward new therapeutic 
intervention.
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